Connect your AI

BioCryst Pharmaceuticals BCRX Earnings yield

Earnings yield at other companies

Ionis PharmaceuticalsIONS

-2.6%-1.1pp

Ultragenyx PharmaceuticalRARE

-29.6%+144pp

ANI PharmaceuticalsANIP

5.3%+4.4pp

AnaptysBio, Inc.ANAB

-9.9%-2.8pp

BridgeBio PharmaBBIO

-5.1%-1.7pp

PVL

Palvella TherapeuticsPVLA

-2.8%-1.1pp

Other financials

Income statement

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Calculated from BioCryst Pharmaceuticals’s reported figures.

net income/market cap=-19.2%

Based on trailing twelve months.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is BioCryst Pharmaceuticals's earnings yield?: BioCryst Pharmaceuticals (BCRX) reported earnings yield of -19.2% in Q1 2026.
How has BioCryst Pharmaceuticals's earnings yield changed year-over-year?: BioCryst Pharmaceuticals's earnings yield decreased by 462.2% year-over-year, from -3.4% to -19.2%.
What is the long-term trend for BioCryst Pharmaceuticals's earnings yield?: Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's earnings yield has grown at a 3.3% compound annual growth rate (CAGR), from -13.6% to 16.1%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.